Work

Phase 2 study of targeted intravenous busulfan (IV BU) combined with fractionated total body irradiation (FTBI) and etoposide (VP-16) as preparative regimen for allogeneic peripheral blood stem cell transplant (PBSCT) for patients with poor risk leukemia

Year: 2006

Type: article

Abstract: Between 3/2000 and 11/2004 30 patients with high risk of relapse post myeloablative SCT received an augmented conditioning regimen consisting of IVBU followed by FTBI 1200 cGy in 10 fractions over 4 days and VP-16 30 mg/kg. BU was administered at 18 mg/m2 targeted for an AUC of 700-900 μM · min every 6 hours × 16 doses. Based on pharmacokinetics, doses for each patient could be adjusted up to a maximum of 32 mg/m2 to achieved targeted AUC. 24 patients had active leukemia (AML 9 induction failure (IF), 7 relapse, 1 untreated MDS evolved to AML, ALL 4 IF and 3 relapse) while 6 patients had remission marrows at time of SCT (3 AML with poor risk cytogenetics and 3 with prior MDS evolved to AML).

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2005.11.108